Van you want to get into Biotech a bit-- This company is very undervalued.
SPRO. This co addresses a huge need-
Spero Therapeutics awarded up to $23M by NIAID for SPR206 development 16:08 SPRO Spero Therapeutics announced that it has been awarded funding of $2.09M with the potential for up to an additional $21.3M over 5 years, from the National Institute of Allergy and Infectious Diseases, NIAID, one of 27 institutes and centers that make up the National Institutes of Health. The funding will support the further clinical development of SPR206, an intravenously (IV)-administered next-generation polymyxin product candidate derived from Spero's potentiator platform that is being developed to treat serious multi-drug resistant Gram-negative infections in the hospital setting. The initial award provides funding for pharmacokinetic/pharmacodynamic studies to aid in dose selection, manufacturing process development, clinical microbiology, and support for regulatory interactions. If fully exercised, the award additionally provides funding for a broad range of activities including new drug application (NDA)-enabling toxicology studies, drug substance, and drug product manufacturing, a Phase 1 absorption, distribution, metabolism, and excretion (ADME) study, and a Phase 2 clinical proof-of-concept study to evaluate the efficacy of SPR206 in target indications.
